Indian Pharma Billionaires Pile Into Generic Weight-Loss Drugs, Sparking Regulatory Scrutiny

The patent expiration last week on semaglutide, the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic for treating diabetes and obesity, triggered a slew of low-cost generics from some of India’s biggest pharmaceutical companies.